logo
logo

Glubio Completes Series A+ Financing Of $22 Million To Advance The Development Of Novel Tpd Drugs

Aug 01, 2022•almost 3 years ago

Round Type

series a

TherapeuticsBiotechnologyHealth Care

Description

GluBio Therapeutics, a biotech company focused on developing novel targeted protein degradation (TPD) drugs, recently announced the completion of Series A+ financing of $22 million. This round is led by Qiming Venture Partners and joined by Lilly Asia Ventures and Kaitai Capital, bringing the total capital raised to nearly $90 million since its establishment in March, 2021.

Company Information

Company

GluBio Therapeutics

About

GluBio Therapeutics is a pioneering TPD company dedicated to developing targeted protein degraders for human diseases with unmet medical needs. Founded by seasoned drug developers with deep knowledge and expertise in TPD drug discovery, the company has established a proprietary TPD discovery platform and robust screening capability. GluBio is advancing a diverse pipeline of highly selective small-molecule degraders across multiple therapeutic areas including oncology and immunology. The company has research operations in both San Diego, CA, USA and Shanghai, China.

FundzWatch™ Score

71
Medium Activity

Buyer Intent Analysis

Get personalized insights on buying likelihood